PDS Biotechnology Corporation cash flow to debt ratio of -163.96K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

PDS Biotechnology Corporation's free cash flow has decreased 79.06K% from $-35.06M last year to $-27.75G, signaling decreasing performance

PDS Biotechnology Corporation's debt to equity ratio is 4.07, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

PDS Biotechnology Corporation's debt has increased relative to shareholder equity from 1.15 last year to 4.07 today, signaling weakened financials

PDS Biotechnology Corporation has negative EBITDA, making leverage ratio unreliable

PDS Biotechnology Corporation's interest coverage ratio is -5.34, which means that the company struggles to meet interest obligations, signaling financial risk.

PDS Biotechnology Corporation has insufficient data to evaluate this check.

PDS Biotechnology Corporation's short-term assets of $28.25M exceed its short-term liabilities of $9.48M

PDS Biotechnology Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

PDS Biotechnology Corporation's return on equity of -346.03%, is lower than 15.00%, indicating bad performance

PDS Biotechnology Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

PDS Biotechnology Corporation had positive net income in only 0.00 out of 5 years, indicating unstable earnings

PDS Biotechnology Corporation has negative free cash flow, indicating the company is burning cash rather than generating it

PDS Biotechnology Corporation has negative free cash flow, indicating cash burn

PDS Biotechnology Corporation's yearly earnings has increased -8.28% since last year from $-37.61M to $-34.50M, signaling increasing performance

PDS Biotechnology Corporation's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -146.60% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

PDS Biotechnology Corporation has insufficient revenue history to calculate 3-year revenue CAGR.

PDS Biotechnology Corporation had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

PDS Biotechnology Corporation had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

PDS Biotechnology Corporation has insufficient data to evaluate this check.

PDS Biotechnology Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

PDS Biotechnology Corporation is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

PDS Biotechnology Corporation has negative or missing EBITDA, making EV/EBITDA ratio unreliable

PDS Biotechnology Corporation has insufficient data to evaluate this check.

PDS Biotechnology Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

PDS Biotechnology Corporation has a price-to-book ratio of 10.73x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

PDS Biotechnology Corporation has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue